Stoke Therapeutics names Thomas Leggett CFO; Stephen Tulipano resigns

Stoke Therapeutics, Inc.

Thomas Leggett appointed CFO effective May 7, 2024; previously CFO at Affinia Therapeutics and Black Diamond Therapeutics.
Leggett receives $475,000 base salary, 40% bonus target, and option for 396,200 shares vesting over 4 years.
Current CFO Stephen Tulipano resigns effective May 7; will serve as advisor through Dec 31, 2024.
Tulipano retains equity vesting during transition period and up to $15,000 in outplacement services.
Leggett holds B.A. from Columbia and M.B.A. from Wharton; also board member at Clover Biopharmaceuticals.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Thomas Leggett

Chief Financial Officer

STOK · Stoke Therapeutics, Inc.

Effective: 2024-05-07
Filed: April 29, 2024, 7:59 PM ET

appointed Thomas Leggett as the Chief Financial Officer of the Company

Departed

Stephen Tulipano

Chief Financial Officer

STOK · Stoke Therapeutics, Inc.

Effective: 2024-05-07
Successor: Thomas Leggett
Filed: April 29, 2024, 7:59 PM ET

Resignation of Chief Financial Officer Effective as of the Appointment Date, the Company’s current Chief Financial Off

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Leggett was appointed as Chief Financial Officer at Stoke Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

appointed Thomas Leggett as the Chief Financial Officer of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Tulipano resigned as Chief Financial Officer at Stoke Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Resignation of Chief Financial Officer Effective as of the Appointment Date, the Company’s current Chief Financial Off

View on SEC.gov

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-122215

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.